Live Breaking News & Updates on Diana kraskouskaya

Stay informed with the latest breaking news from Diana kraskouskaya on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Diana kraskouskaya and stay connected to the pulse of your community

Dalriada brings in former Evotec executive Adam Davenport

TORONTO, May 03, 2023 (GLOBE NEWSWIRE) -- Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, announces...

Toronto , Ontario , Canada , Canadian , Adam-davenport , Diana-kraskouskaya , Research-development , Dalriada-drug-discovery-inc , Women-health , Chief-research , Development-officer , Global-molecular-discovery

Dalriada further strengthens small molecule discovery

TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Dalriada, a leading Canadian contract research organization specializing in small molecule therapies,...

Canada , Toronto , Ontario , Canadian , Diana-kraskouskaya , Dalriada-drug-discovery-inc , Lundbeck , Thermo-fisher , Frosty-loechel , Discovery-strategy , Metabolic-diseases , Therapeutic-area-lead

atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health TreatmentsInvyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs)Early focus will be on designing unique, novel compound...

New-york , United-states , Chad , Berlin , Germany , London , City-of , United-kingdom , Camilla-dormer , Diana-kraskouskaya , Srinivas-rao , Exchange-commission

Dalriada Drug Discovery to Collaborate with atai Life Sciences' New Platform Company to Discover Next-Generation Therapies for Mental Health

Dalriada Drug Discovery to Collaborate with atai Life Sciences’ New Platform Company to Discover Next-Generation Therapies for Mental Health  Invyxis to leverage Dalriada’s agile Turn-KeyTM model to establish and rapidly advance a pipeline of NCEs in mental health This strategic collaboration w...

Toronto , Ontario , Canada , Diana-kraskouskaya , Life-science-new-platform-company-to-discover , Life-sciences , Generation-therapies-for-mental-health , Dalriada-drug-discovery , Life-science-new-platform-company , Discover-next-generation-therapies , Mental-health , Drug-discovery

atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai's portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel

New-york , United-states , Chad , Berlin , Germany , London , City-of , United-kingdom , Camilla-dormer , Diana-kraskouskaya , Srinivas-rao , Exchange-commission

Dalriada Drug Discovery to Collaborate with atai Life Sciences' New Platform Company to Discover Next-Generation Therapies for Mental Health

- Invyxis to leverage Dalriada's agile Turn-KeyTM model to establish and rapidly advance a pipeline of NCEs in mental health - This strategic collaboration with atai Life Sciences

New-york , United-states , Canada , Toronto , Ontario , Berlin , Germany , London , City-of , United-kingdom , Canadian , Sacha-kennedy

Dalriada Drug Discovery to Collaborate with atai Life Sciences' New Platform Company to Discover Next-Generation Therapies for Mental Health

/PRNewswire/ -- Dalriada Drug Discovery ("Dalriada") is pleased to announce a strategic collaboration with atai Life Sciences' N.V. (Nasdaq: ATAI) newly...

New-york , United-states , Canada , Toronto , Ontario , Berlin , Germany , London , City-of , United-kingdom , Canadian , Sacha-kennedy

Novartis Jumpstarts Presence in Protein Degradation with Up-to-$1.3B Dunad Collaboration

Novartis will partner with Dunad Therapeutics to develop oral covalent and protein degrading small molecule drugs for undisclosed diseases, through a collaboration that could generate more than $1.3 billion for Dunad and revive a presence in the segment for Novartis.

Berkeley , California , United-states , United-kingdom , Amsterdam , Noord-holland , Netherlands , British , Diana-kraskouskaya , Eli-lilly , University-of-california , Pfizer